Q-linea signs evaluation contract with reference laboratory network in the US
Q-linea signs evaluation contract with reference laboratory network in the US
Q-linea AB (publ) (OMX:QLINEA) today announces that the company has signed an evaluation contract with a large network reference laboratory headquartered in the United States.
With the announcement of FDA clearance of the ASTar System and a Gram-negative panel (ASTar BC G- Consumable Kit), Q- linea has already signed a contract under the Early Evaluation Program with a large network reference laboratory and is in active conversations with several hospital systems for the same. Jim Kathrein, VP of US Commercial Operations, said: “Early interest in ASTar has been extremely positive and we are excited to demonstrate our fully automated rapid AST capabilities in the US market. We anticipate seeing continued strong results in line with our EAP data and European placements.”